Navigation Links
Research finds surgery outperforms drug therapy in treatment of benign prostatic hyperplasia
Date:5/29/2010

SAN FRANCISCO A 17-year-long community study looking at symptoms of enlarged prostate in over 2,000 men age 40 to 79 years suggests that surgery for benign prostatic hyperplasia (BPH) offers more relief from incontinence and obstruction symptoms than treatment from drug-based therapy, according to a new study by researchers at Mayo Clinic. The researchers presented their results today at the annual meeting of the American Urological Association.

Overall, results show:

  • Urinary incontinence was a common condition, coexisting with BPH/lower urinary tract symptoms.
  • In the community setting, patients with the highest symptom scores were most likely to receive surgical intervention.
  • Symptoms stabilized and did not get worse after treatment of all kinds.
  • Patients who underwent transurethral resection of the prostate (TURP) had the greatest decrease in both symptoms and incontinence compared to other treatment groups. Pre-TURP the incontinence rate was 64.5 percent and post-TURP it was 41.9 percent.

Significance

The findings provide large-sample, long-term data comparing the effectiveness of medical versus surgical treatments in a large, general population, as compared to small, select clinical populations of men. "Our data fills a gap in the research record that can be used by physicians and patients to evaluate management options," says Amy Krambeck, M.D., Mayo Clinic urologist and lead study investigator. "Because it's a large community-based study of more than 2,100 men, it includes the entire broad range of male health. This suggests the results are stronger in terms of being generalized and applied to other men."

Background

BPH and lower urinary tract symptoms, such as frequent urge to urinate or leakage, are common. By age 60, an estimated 50 percent of all men suffer from enlarged prostate symptoms; by age 90, about 80 percent do. Multiple treatments exist. But data comparing drug therapy to surgery are lacking, making clinical decisions vulnerable to subjective factors.

About the Study

From 1990 through 2007, the study enrolled 2,184 healthy men, age 40-79, living in Olmsted County, Minn., All participants completed surveys every other year about their urinary symptoms and the treatments they received. From this information, the investigators examined urinary problems and incontinence before and after different types of treatment.

Results showed that of the 2,184 men:

  • 1,574 (72%) received no treatment for BPH symptoms.
  • 307 (14%) took alpha adrenergic receptor blockers (α-ARs).
  • 195 (9%) took the medication 5-alpha-reductase inhibitors (ARIs).
  • 23 (1%) received surgical laser vaporization.
  • 85 (4%) received surgical transurethral resection of the prostate (TURP).

Comments Dr. Krambeck: "After intervention, the greatest improvement in symptom score was seen in the TURP group, followed by laser vaporization, then the drugs, 5 alpha reductase inhibitors and alpha adrenergic receptor blockers. Only the surgical TURP group reported a decrease in incontinence pre-TURP the incontinence rate was 64.5 percent and post-TURP it was 41.9 percent." This reduction in incontinence rates is significant when compared to the increase in reported incontinence in the patients receiving both forms of medical therapy and no change in symptoms for patients receiving laser vaporization.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Researchers report no difference in breast cancer characteristics after oophorectomy
2. Vanderbilt researchers play major role in new center on electronic health information privacy
3. New research at the University of Leicester links shoplifting to your personality
4. OHSU joins forces with UO, Harvard to accelerate Fanconi anemia research
5. Pitt researchers discover gene mutation linked to lymphatic dysfunction
6. Researchers validate a new test for assessing childrens and teenagers fitness to prevent morbidity
7. Chef Charles Phillips of Nashville's 1808 Grille, Teams up with National Foundation for Cancer Research, Offering Gourmet Healthy Living Options
8. Rensselaer researcher wins $1.4 million NIH grant to enable faster cancer treatment planning
9. NIH awards $10M to Einstein for diabetes research
10. H1N1, Biodegradable Plastics and Nuclear Physics Highlight Research Areas Undertaken During Houghton College's Summer Research Institute
11. Novel anti-malarial drug candidate found by UT Southwestern researchers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... , ... March 27, 2017 , ... ... comprehensive weight management program at Women’s Excellence will help patients lose weight and ... physical exam. The specialists at Women's Excellence will measure BMI, body fat ...
(Date:3/27/2017)... ... 2017 , ... Janet Schloz is still in shock after receiving a $2,500 Academic Award from ... long time,” she said. , She thinks the coming week is going to be a ... would have to help my students.” , The award will allow the 4th grade teacher ...
(Date:3/27/2017)... ... March 27, 2017 , ... ?Grow Healthy Vending ... the pending litigation between itself and 1800 Vending DBA Healthy You Vending. (Civil ... am thrilled to announce that we have now reached a settlement agreement regarding ...
(Date:3/26/2017)... Columbus, Ohio (PRWEB) , ... March 26, 2017 ... ... 100 doctors worldwide to receive the RealSelf 100 Award, a prestigious award honoring ... elective cosmetic procedures and to find and connect with doctors and clinics. , ...
(Date:3/24/2017)... ... 24, 2017 , ... Mediaplanet today announces distribution of its ... obstacles facing infection prevention and offer strategies for the health care community to ... , The print component of “Fighting Infection” is distributed within the Friday, March ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... , March 27, 2017  PhaseRx, Inc. (NASDAQ: ... life-threatening inherited liver diseases in children, today reported ... year ended December 31, 2016 and provided an ... "PhaseRx continued to make progress during the fourth ... results from our non-human primate safety study, and with ...
(Date:3/24/2017)... , Mar 24, 2017 Research and ... Manufacturing Market, 2017-2027" report to their offering. ... The Cell Therapy ... rapidly growing market of cell therapy manufacturing and focuses both ... facilities. These therapies are anticipated to emerge as viable alternatives ...
(Date:3/24/2017)... March 24, 2017  Zymo Research Corp., ... Hamilton Robotics, Inc., who designs, manufactures and ... collaboration that teams Zymo Research,s DNA methylation ... DNA extraction products with Hamilton,s high-throughput automation ... methods for microbiomics and RNA isolation for ...
Breaking Medicine Technology: